NeoGraph Analytics
Medical DevicesGlobal2026 – 2033

Orthopedic Implants Market Size, Share & Forecast 2026-2033

Five companies disclose $34.4B of orthopaedic revenue -- 21% more than the narrowest published global market contains. The scope test, with the arithmetic.

Revenue, 2026

$48.4B

Forecast, 2033

$70.9B

CAGR, 2026-2033

5.6%

Report Coverage

Global

Code: orthopedic-implants-marketPublished: 2026Pages: 150+Format: PDF + Excel
01

Executive Summary

Published estimates of the orthopedic implants market put its 2025 or 2026 base between $28.45 billion and $61.61 billion -- a 2.17x spread. The published growth rates run only from 3.97% to 5.8%, a 1.46x spread. Nobody really disagrees about how fast this market grows. They disagree about what is in it.

This is the best-disclosed market we have examined, and that makes the disagreement settleable. Five companies disclose orthopaedic segment revenue outright: Stryker's Orthopaedics segment at $9,469 million for 2025, Zimmer Biomet's whole company at $8,232 million, Johnson & Johnson's Orthopaedics franchise at $9,258 million, Smith+Nephew's Orthopaedics segment at $2,437 million, and Medtronic's Cranial & Spinal Technologies division at $4,973 million for a fiscal year ended April 2025. Those five sum to $34,369 million.

That sum is 120.8% of 360iResearch's entire published global market of $28.45 billion -- five companies disclosing 21% more revenue than the whole market is said to contain. Zimmer Biomet alone, an orthopaedics pure-play whose revenue is therefore a hard floor on any definition including knees and hips, is 28.9% of it; Zimmer Biomet plus Stryker Orthopaedics is 62.2%. Neither is possible in an industry that also contains Globus Medical, Arthrex, Medacta, B.Braun Aesculap, Enovis and the whole Chinese domestic supply base.

Against Persistence Market Research's $48.4 billion for 2026 the same five disclosures are 71.0% -- high, but plausible for an industry whose top five are known to dominate it. A second test confirms the order of magnitude: the four reconstructive players disclose $14,850 million of knee and hip implant revenue, which against OECD-implied hip and knee replacement volume is about $3,040 per procedure, inside the measured per-case implant cost range. We publish $48.4 billion for 2026 rising to $70.9 billion by 2033 at 5.6%, and name the three scope decisions that move the number.

02

Key Highlights

1

Published base-year estimates spread 2.17x ($28.45B to $61.61B) while published CAGRs spread only 1.46x (3.97% to 5.8%)

2

Five disclosed orthopaedic revenue lines sum to $34.37B for 2025 -- 120.8% of the narrowest published global market and 71.0% of the broadest

3

Zimmer Biomet, an orthopaedics pure-play, is 28.9% of the narrow market on its own; with Stryker Orthopaedics the two are 62.2% of it

4

Disclosed knee and hip implant revenue of $14,850M is about $3,040 per OECD hip or knee replacement, inside a measured $1,797-$12,093 per-case implant cost range

5

Trauma and extremities now exceeds knees at both Stryker ($3,948M) and J&J ($3,146M)

6

Stryker's Spinal Implants line is only $185M of a $9,469M Orthopaedics segment after divesting its US spine business, while Medtronic's spine division alone is $4,973M

7

OECD hip and knee replacement rates rose from 172 and 119 per 100,000 in 2021 to 198 and 156 in 2023

03

Market Overview

Market Context

The word that moves this market's size is not implant, it is skeletal. Three product families sit inside or outside a published figure depending on the analyst, and each is worth billions. Spinal implants are the first. Persistence names them as a product type; a reconstructive-only reading excludes them. Medtronic alone disclosed $4,973 million of Cranial & Spinal Technologies revenue for its fiscal 2025, more than a sixth of the narrowest published global market on its own. Stryker, by contrast, reported Spinal Implants of just $185 million within a $9,469 million Orthopaedics segment, having divested its US spinal implants business -- so a reader who treats Stryker's orthopaedic revenue as covering spine is reading the wrong company. Trauma fixation and craniomaxillofacial implants are the second. They are the largest single line in two of the five big disclosures: Stryker's Trauma and Extremities was $3,948 million in 2025 and J&J's Trauma was $3,146 million -- each larger than either company's knee or hip business. Dental implants are the third. No source in our set states whether dental is in or out, except Persistence by omission. It is the most common silent inclusion in any category called implants, and it is the first question to ask of any figure quoted in this market.

On the broad definition we adopt -- reconstructive joint replacement, spinal implants, trauma fixation and craniomaxillofacial implants, excluding dental -- the orthopedic implants market is $48.4 billion in 2026, projected to $70.9 billion by 2033 at a 5.6% CAGR. A narrower reading published by 360iResearch puts 2025 at $28.45 billion, but five companies disclose $34.37 billion of orthopaedic segment revenue between them, exceeding that whole market by 21%, and two of them alone are 62.2% of it. The spread across published bases is 2.17x; across published growth rates it is only 1.46x.

Market Stage

Mature

Adoption Level

Standard of care; growth comes from volume and mix rather than from new adoption

Key Trends

Published base-year estimates spread 2.17x ($28.45B to $61.61B) while published CAGRs spread only 1.46x (3.97% to 5.8%)Five disclosed orthopaedic revenue lines sum to $34.37B, which is 120.8% of the narrowest published global market and 71.0% of the broadestTrauma and extremities is now larger than knees or hips at both Stryker ($3,948M) and J&J ($3,146M), reversing the usual mental model of this marketDisclosed knee and hip implant revenue works out at about $3,040 per OECD hip or knee replacement, inside the measured per-case implant cost rangeOECD hip and knee replacement rates rose from 172 and 119 per 100,000 in 2021 to 198 and 156 in 2023, so procedure volume is growing faster than the published revenue CAGRsPortfolio reshaping is accelerating: J&J plans to spin off orthopaedics within 18 to 24 months, Stryker has exited US spinal implants, and Zimmer Biomet bought Paragon 28
04

Market Forecast & Data

Market Growth Forecast
2026-2033 · CAGR 5.6%

Base Year (2026)

$48.4B

Forecast (2033)

$70.9B

CAGR (2026-2033)

5.6%

Market size by year, 2026-2033, in USD Billion.
YearMarket size ($ Billion)
2026Base year$48.40B
2027$51.11B
2028$53.97B
2029$56.99B
2030$60.18B
2031$63.55B
2032$67.11B
2033$70.90B
Source: NeoGraph Analytics, tabulated from the base-year and forecast values stated in this report. Modelled at constant CAGR between published endpoints. How these figures are produced.
Forecast Analysis

The headline comes from Persistence Market Research, read from the publisher's own page on 16 October 2026: $48.4 billion for 2026, $70.9 billion for 2033, a 5.6% CAGR for 2026-2033, against a published historical $37.3 billion for 2020 at a 4.4% historical rate. Both endpoints are the publisher's own published figures rather than derivations, which is unusual, and the arithmetic closes: 48.4 x 1.056^7 = 70.88 against the published 70.9, an implied 5.61% against a stated 5.6%. The intermediate years shown here are interpolation at that rate, not separately sourced observations. It was chosen because it is the only source in the set we could read directly from the publisher's own page -- every competing figure came through a search summary, one publisher page returned HTTP 403, and one attribution could not be verified at all -- and because it is the only one with a fully stated product scope naming reconstructive joints, spinal implants, trauma fixation and CMF. That is precisely the decision that moves this market's base by 2.17x. It is also the series the disclosed record supports. At $48.4 billion, five disclosed segment revenue lines are 71.0% of the market; at $28.45 billion they are 120.8% of it. Readers should treat a published growth rate here as the stable part of the literature and a published base as a scope statement.

05

Market Dynamics

  • Rising procedure rates in the register: OECD hip replacements went from 172 to 198 per 100,000 and knees from 119 to 156 between the 2021 and 2023 data years
  • Ageing populations in the high-rate OECD countries, where Germany already performs about 351 hip replacements per 100,000
  • Migration of joint replacement into ambulatory surgical centres, which Persistence names as the growing end-user channel
  • Robotic and enabling-technology platforms pulling implant volume through: J&J credits VELYS pull-through for knee growth and Medtronic credits the AiBLE ecosystem for spine
  • Extremities and trauma, where Zimmer Biomet's S.E.T. line grew 15.2% in 2025 with 10.5 points of that from the Paragon 28 acquisition
06

Market Segmentation

By Type

  • Reconstructive joint replacement (knee implants, hip implants)
  • Spinal implants
  • Trauma fixation implants
  • Craniomaxillofacial implants
  • Extremities and sports medicine implants

By End User

  • Hospitals
  • Ambulatory surgical centres
  • Orthopaedic specialty clinics

By Application

  • Osteoarthritis
  • Traumatic fracture
  • Rheumatoid arthritis
  • Osteoporosis
  • Degenerative spinal disease
07

Competitive Landscape

S

Stryker

United States

Largest disclosed orthopaedic segment

Reported Orthopaedics net sales of $9,469 million for 2025 within total company sales of $25,116 million: Knees $2,656 million, Hips $1,865 million, Trauma and Extremities $3,948 million, Other $815 million and Spinal Implants only $185 million following the divestiture of its US spinal implants business. Segment growth was 4.3% reported but 9.5% organic, with acquisitions and divestitures costing 5.7 points, driven by unit volume against 0.1% lower prices. Its trauma and extremities business is more than twice its knee business, which is the fact most readers of this market get wrong.

J

Johnson & Johnson (DePuy Synthes)

United States

Comparable scale, being separated

Reported Orthopaedics worldwide sales of $9,258 million for 2025, up 1.1%: Trauma $3,146 million, Spine, Sports & Other $2,852 million, Hips $1,674 million and Knees $1,587 million. Growth was held back by an orthopaedics restructuring now largely complete, China volume-based procurement and fewer selling days. J&J has announced plans to spin off the orthopaedics business within 18 to 24 months, describing it as slow-growing.

Z

Zimmer Biomet

United States

Orthopaedics pure-play; a floor on the market definition

Essentially the whole company is this market, which makes its $8,232 million of 2025 net sales a hard floor on any market definition that includes knees and hips. Knees were $3,322.3 million and Hips $2,093.5 million, each up 4.7% reported, and S.E.T. was $2.15 billion, up 15.2% with 10.5 points of that from the Paragon 28 acquisition. Total net sales rose 7.2% reported but only 3.9% organic constant currency. That $8,232 million is 28.9% of the narrowest published global market, which is one of the reasons the narrow reading cannot stand.

M

Medtronic (Cranial & Spinal Technologies)

Ireland / United States

Largest disclosed spinal implant business

Disclosed $4,973 million of Cranial & Spinal Technologies net sales for the fiscal year ended 25 April 2025, up 5%, inside a Neuroscience segment of $9,846 million. Growth is attributed to the AiBLE spine implant and enabling-technology ecosystem, with gains in Core Spine, Biologics and Neurosurgery. Whether this revenue is inside or outside a quoted orthopedic implants figure is the single largest scope question in the category.

S

Smith+Nephew

United Kingdom

Fifth disclosing player, reconstructive focus

Reported Orthopaedics segment revenue of $2,437 million for 2025, up 5.7% reported and 5.1% underlying, with Knee Implants of $1,011 million and Hip Implants of $641 million, each up 3.5%. Robotics consumables were reclassified into the knee and hip lines so prior years are restated. A trade source reports a $4.15 billion orthopaedic figure for the same company that additionally includes Sports Medicine and Enabling Technology and is not comparable with the segment line.

G

Globus Medical, Arthrex, Medacta, B.Braun Aesculap, Enovis and the Chinese domestic suppliers

Various

The unmeasured remainder

None of these is inside the five-company sum used in this report, and most do not publish a comparable orthopaedic segment line. On the broad published reading they share roughly $14 billion of revenue between them; on the narrow reading there is no room for them at all, which is the arithmetic that rules the narrow reading out. No share is asserted for any of them.

08

Recent Developments

26
2026Johnson & Johnson

Reported full-year 2025 Orthopaedics sales of $9,258 million, up only 1.1%, and announced plans to spin off the orthopaedics business within 18 to 24 months, describing it as slow-growing. China volume-based procurement and an orthopaedics restructuring were cited as pressures on every platform.

26
2026Stryker

Reported 2025 Orthopaedics net sales of $9,469 million with Spinal Implants of only $185 million following divestiture of its US spinal implants business; acquisitions and divestitures reduced reported segment growth by 5.7 points against 9.5% organic growth.

26
2026Zimmer Biomet

Reported 2025 net sales of $8.232 billion, up 7.2% reported but 3.9% organic constant currency, with S.E.T. revenue up 15.2% of which 10.5 percentage points came from the Paragon 28 foot and ankle acquisition, and guided 2026 revenue growth of 2.5% to 4.5%.

25
2025Medtronic

Reported Cranial & Spinal Technologies net sales of $4,973 million for the fiscal year ended 25 April 2025, up 5% on $4,756 million, attributing growth to the AiBLE spine implant ecosystem and enabling technology across Core Spine, Biologics and Neurosurgery, and recast prior-period net sales to a new presentation.

25
2025American Academy of Orthopaedic Surgeons

Published the twelfth American Joint Replacement Registry Annual Report, analysing 4,434,668 validated hip and knee arthroplasty procedures collected from 2012 through 2024 across all 50 states, up 20% from 3,715,320 in the prior edition, from over 5,000 surgeons and 1,200 institutions.

09

Regulatory Landscape

FDA device classification for orthopaedic devices under 21 CFR Part 888, under which most hip and knee prostheses clear by 510(k) as Class II while certain implants require premarket approvalEU Medical Device Regulation 2017/745, which classifies total joint replacement implants as Class III and requires clinical evaluation and post-market clinical follow-up for eachCMS removal of total knee arthroplasty (2018) and total hip arthroplasty (2020) from the Medicare inpatient-only list, which opened outpatient and ambulatory surgical centre settings to these proceduresCMS bundled payment models for lower-extremity joint replacement, which place the implant inside a fixed episode payment and transfer price risk to the providerChina's centralised volume-based procurement for orthopaedic implants, cited by Johnson & Johnson as a pressure on every orthopaedics platformNational arthroplasty registry reporting, including the American Joint Replacement Registry and equivalent national registries, which conditions post-market surveillance evidence for implant systems
10

Research Methodology

Primary research

  • No primary interviews were conducted for this edition. This report is a synthesis of SEC and 20-F filings, the OECD health statistics, a national arthroplasty registry report and published third-party estimates, and is labelled as such rather than implying fieldwork that did not occur.

Secondary research

  • Stryker Corporation, 2025 operating results, filed as exhibit 99.1 to a Form 8-K (29 January 2026): Orthopaedics $9,469M with knees, hips, trauma and spinal implant lines
  • Zimmer Biomet Holdings, Q4 and full-year 2025 results (10 February 2026) and FY2025 Form 10-K: net sales $8.232 billion, Knees $3,322.3M, Hips $2,093.5M
  • Johnson & Johnson, Q4 and Full Year 2025 results (January 2026): Orthopaedics $9,258M with Hips, Knees, Trauma and Spine/Sports/Other lines
  • Smith & Nephew plc, FY2025 Form 20-F: Orthopaedics $2,437M, Knee Implants $1,011M, Hip Implants $641M
  • Medtronic plc, Q4 fiscal 2025 results, exhibit 99.1 to a Form 8-K (fiscal year ended 25 April 2025): Cranial & Spinal Technologies $4,973M
  • OECD, Health at a Glance 2025, hip and knee replacement (2023 data): OECD averages of 198 hip and 156 knee replacements per 100,000 population
  • AAOS American Joint Replacement Registry 2025 Annual Report: 4,434,668 validated hip and knee arthroplasties, 2012-2024
  • Published market estimates from Persistence Market Research (read from the publisher's page, 16 October 2026), 360iResearch, HNY Research, Allied Market Research and a Fortune Business Insights attribution

Validation: Market size is taken from published third-party estimates, attributed by name, and presented as published estimates rather than verified measurements. Two grounding tests were run. First, five disclosed orthopaedic revenue lines for 2025 were summed -- Stryker $9,469M, Zimmer Biomet $8,232M, Johnson & Johnson $9,258M, Smith+Nephew $2,437M and Medtronic Cranial & Spinal Technologies $4,973M, totalling $34,369M -- and divided by each publisher's base-year total, giving 71.0% of Persistence's $48.4 billion and 120.8% of 360iResearch's $28.45 billion. Zimmer Biomet alone is 28.9% of the latter and Zimmer Biomet plus Stryker Orthopaedics 62.2%. Second, the four reconstructive players' disclosed knee and hip implant revenue of $14,850M was divided by hip and knee replacement volume implied by OECD rates of 198 and 156 per 100,000 against the OECD population, giving roughly $3,040 per procedure against a measured per-case implant cost range of $1,797 to $12,093. These tests establish that the narrowest published series cannot be the whole market and that the broad reading is in the right order of magnitude. They do not establish the correct market size for either scope. Medtronic's fiscal year ends in April and is not coterminous with the other four; Zimmer Biomet's figure is whole-company revenue, not an implant-only line; the OECD population multiplier is our own sum of member populations against an average that is probably unweighted, so the procedure figure is an estimate rather than a count; the per-case implant cost comparator is from 2008 and US-only; and dividing company revenue by a third party's market total compares differently constructed numbers. No vendor market share is published because none is disclosed, and no regional or country split is published because no named source gives a numeric share of the global total.

11

Strategic Takeaways

Before quoting an orthopedic implants market size, establish whether spine, trauma, CMF and dental are inside it -- those four decisions move the base by 2.17x

Treat any figure near $28 billion as reconstructive joints at most

five companies disclose 21% more revenue than that whole market is said to contain

Use Zimmer Biomet's whole-company revenue as a floor test on any definition that includes knees and hips, because that is effectively all the company does

Trauma and extremities, not joints, is the largest orthopaedic line at two of the three biggest players -- plan against the disclosed mix, not the mental model

Procedure rates are growing faster than revenue, so model price deflation explicitly rather than assuming volume converts to revenue one for one

12

Frequently Asked Questions

Reports in the same field, each with its base-year figure and the growth rate it is published at.